Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neuroblastoma 1Hepatoblastoma 1Head and Neck Neoplasms 1HER2 Positive Advanced Gastric Cancer 1Basal Cell Carcinoma of the Head and Neck 1

Interventions

Cisplatin 176Paclitaxel 79Radiotherapy 76Carboplatin 70Brachytherapy 69pembrolizumab 63Bevacizumab 40Gemcitabine 28Radiation 27Topotecan 26Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 25Nivolumab 22Colposcopy 22human papillomavirus vaccine, L1 type 16, 18 21Magnetic Resonance Spectroscopy 21atezolizumab 19Platinum 19Drug Therapy 19Papillomavirus Vaccines 18Radiotherapy, Intensity-Modulated 17Docetaxel 17Taxes 16Cyclophosphamide 16Biopsy 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14Blood Specimen Collection 14fludarabine 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Uterine Cervical Neoplasms × Tissue Banks × Clear all
NCT00298064 2023-07-05

Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

University of New Mexico

Phase NA Withdrawn
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡